THE Therapeutic Goods Administration (TGA) has approved Novartis' drug Mayzent (siponimod), for adults with secondary progressive multiple sclerosis.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Nov 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Nov 19